Eiger BioPharmaceuticals EIGR Stock
Eiger BioPharmaceuticals Price Chart
Eiger BioPharmaceuticals EIGR Financial and Trading Overview
| Eiger BioPharmaceuticals stock price | 1.73 USD |
| Previous Close | 0.95 USD |
| Open | 0.94 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 800 |
| Day's Range | 0.94 - 1 USD |
| 52 Week Range | 0.75 - 9.89 USD |
| Volume | 117.97K USD |
| Avg. Volume | 331.84K USD |
| Market Cap | 43.08M USD |
| Beta (5Y Monthly) | 1.890218 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 USD |
EIGR Valuation Measures
| Enterprise Value | 6.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.6947143 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.885838 |
| Price/Book (mrq) | 1.2218592 |
| Enterprise Value/Revenue | 0.434 |
| Enterprise Value/EBITDA | -0.07 |
Trading Information
Eiger BioPharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.890218 |
| 52-Week Change | -82.74% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.89 USD |
| 52 Week Low | 0.75 USD |
| 50-Day Moving Average | 1.08 USD |
| 200-Day Moving Average | 2.88 USD |
EIGR Share Statistics
| Avg. Volume (3 month) | 331.84K USD |
| Avg. Daily Volume (10-Days) | 283.45K USD |
| Shares Outstanding | 44.3M |
| Float | 35.16M |
| Short Ratio | 9.77 |
| % Held by Insiders | 11.43% |
| % Held by Institutions | 61.09% |
| Shares Short | 2.47M |
| Short % of Float | 6.65% |
| Short % of Shares Outstanding | 5.58% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -624.17% |
| Gross Margin | 87.64% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.11% |
| Return on Equity (ttm) | -146.28% |
Income Statement
| Revenue (ttm) | 14.93M USD |
| Revenue Per Share (ttm) | 0.34 USD |
| Quarterly Revenue Growth (yoy) | 54.10% |
| Gross Profit (ttm) | 11.65M USD |
| EBITDA | -92890000 USD |
| Net Income Avi to Common (ttm) | -96917000 USD |
| Diluted EPS (ttm) | -2.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 80.02M USD |
| Total Cash Per Share (mrq) | 1.81 USD |
| Total Debt (mrq) | 40.43M USD |
| Total Debt/Equity (mrq) | 114.72 USD |
| Current Ratio (mrq) | 4.038 |
| Book Value Per Share (mrq) | 0.796 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -88556000 USD |
| Levered Free Cash Flow (ttm) | -54136248 USD |
Profile of Eiger BioPharmaceuticals
| Country | United States |
| State | CA |
| City | Palo Alto |
| Address | 2155 Park Boulevard |
| ZIP | 94306 |
| Phone | 650 272 6138 |
| Website | https://www.eigerbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 51 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Q&A For Eiger BioPharmaceuticals Stock
What is a current EIGR stock price?
Eiger BioPharmaceuticals EIGR stock price today per share is 1.73 USD.
How to purchase Eiger BioPharmaceuticals stock?
You can buy EIGR shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eiger BioPharmaceuticals?
The stock symbol or ticker of Eiger BioPharmaceuticals is EIGR.
Which industry does the Eiger BioPharmaceuticals company belong to?
The Eiger BioPharmaceuticals industry is Biotechnology.
How many shares does Eiger BioPharmaceuticals have in circulation?
The max supply of Eiger BioPharmaceuticals shares is 0.
What is Eiger BioPharmaceuticals Price to Earnings Ratio (PE Ratio)?
Eiger BioPharmaceuticals PE Ratio is now.
What was Eiger BioPharmaceuticals earnings per share over the trailing 12 months (TTM)?
Eiger BioPharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Eiger BioPharmaceuticals company belong to?
The Eiger BioPharmaceuticals sector is Healthcare.
Eiger BioPharmaceuticals EIGR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}